Lilly Expands U.S. Operations with $6 Billion Huntsville Manufacturing Facility
Introduction
Eli Lilly and Company (NYSE: LLY) has announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The facility will focus on producing active pharmaceutical ingredients (APIs) for small molecule synthetic and peptide medicines and will be one of four new U.S. sites the company plans to develop.
Features
The new facility will produce Lilly’s first oral, small molecule GLP-1 receptor agonist, orforglipron, for obesity treatment, with regulatory submissions expected by the end of the year.
It will create around 450 high-value jobs, including roles for engineers, scientists, lab technicians, and operations staff, while construction, starting in 2026, is expected to generate approximately 3,000 jobs.
The site will use advanced technologies such as machine learning, artificial intelligence, digital monitoring systems, and data analytics to ensure efficient and accurate production. Sustainable practices will be a priority, with measures to reduce waste and achieve carbon neutrality.
The facility is scheduled to be completed in 2032, strengthening Lilly’s U.S. manufacturing presence and supporting supply chain resilience for essential medicines.
Specifications
| Name | Eli Lilly |
| Budget | $6 Billion |
| Type | Construction |
| Year of Completion | 2032 |
